Fig. 6From: Ribonucleic acid interference knockdown of IL-6 enhances the efficacy of cisplatin in laryngeal cancer stem cells by down-regulating the IL-6/STAT3/HIF1 pathwayXenograft cancer tissues (a) derived from hep2-CSC (i), hep2-CSC treated with siRNA-IL-6 (ii), hep2-CSC treated with cisplatin (iii) and hep2-CSC treated with siRNA-IL-6 and cisplatin (iv). Measure of tissue size (b) indicated that tumor growth was significantly decreased by siRNA-IL-6, cisplatin or the combined treatments, as compared to the hep2-CSC control. ***p < 0.001 vs CSC control; #p < 0.05 vs CSC-Cisplatin groupBack to article page